A Phase 1/2 interventional study of trastuzumab and paclitaxel in Breast Cancer, sponsored by Hoffmann-La Roche. Completed at 1 site in Spain. Open to female participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2015-03-12.
Sponsored by Hoffmann-La Roche · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 374 studies testing trastuzumab in Breast Neoplasms — 57 open to participants now, 86 under way, 5 of them phase 3. Trastuzumab · Breast Neoplasms.
Among the 374 studies testing trastuzumab in Breast Neoplasms, this one is the 167th largest by enrollment of the 366 interventional ones that give a count, is one of 13 that started in 2001, is one of 30 in phase 1/2, and was the 213th registered.
14,837 studies on the registry are indexed under Breast Neoplasms; 3,320 are open to participants now.
Browse Breast Neoplasms studies →57 of the 374 studies testing trastuzumab in Breast Neoplasms are open now, in 12 countries. Recruiting first, the newest first:
SWOG Cancer Research Network · Sites in United States
Ages 18+
Duke University · Sites in United States
Ages 18+ · Women only
Rutgers, The State University of New Jersey · Sites in United States
Ages 18–90
Shanghai Jiao Tong University School of Medicine · Sites in China
Ages 18–70 · Women only
Institut Curie · Sites in France
Ages 18+
By country, each count listing its studies:
Trastuzumab: first FDA approval 1998 (HERCEPTIN), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →
Of the 2,399 Breast Neoplasms studies recruiting now, 1,570 (65%) set no upper age limit and 592 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 18 Years to 70 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, trastuzumab is the treatment under test here. Read study by study →
374 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 51 · Phase 2 270 · Phase 3 61 · Phase 4 7
First in 1998; this study’s year is marked. 13 started in 2001.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 69 is close to the median of 72 across 10,903 interventional studies indexed under Breast Neoplasms.
Median enrollment 61 across the 366 interventional studies. Of the 235 that completed or were terminated, 128 (54%) have results posted.
This tab as a report to print or save as PDF → With an account.
73 of 374 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
229 studies in Breast Neoplasms by Hoffmann-La Roche: 16 open now, 28 under way, 13 of them phase 3. Of 193 finished, 120 (62%) have results posted.
Among the 229 studies in Breast Neoplasms by Hoffmann-La Roche, this one is the 123rd largest by enrollment of the 170 interventional ones that give a count, is one of 4 that started in 2001, is one of 11 in phase 1/2, and was the 122nd registered.
Hoffmann-La Roche’s Breast Neoplasms studies by the year they started, since 1998.
22 of the studies testing trastuzumab in Breast Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06035679Youzhi ZhuPyrotinib Combined With Trastuzumab and Chemotherapy Neoadjuvant Therapy for HER2-positive Breast Cancer | 2026-11-30 |
| NCT05891561Shanghai Jiao Tong University School of MedicineShort-course Trastuzumab, Pertuzumab with Taxanes in the Adjuvant Treatment of Early HER2-positive Breast Cancer | 2026-12 |
| NCT04886531Ruth O'ReganTrial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers | 2026-12-22 |
| NCT07095023Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNeoadjuvant Oral Paclitaxel Plus Subcutaneous Pertuzumab/Trastuzumab in Patients With HER2-positive Breast Cancer | 2026-12-30 |
| NCT07635342Hebei Medical University Fourth HospitalPyrotinib Plus Trastuzumab and Chemotherapy for HER2-Positive Early Breast Cancer | 2026-12-31 |
Add all 22 to your calendar (.ics) → With an account.
Among the 374 studies testing trastuzumab in Breast Neoplasms, from their registry updates:
Among Hoffmann-La Roche’s 229 in Breast Neoplasms:
This tab as a report to print or save as PDF → With an account.
This study will define an optimal chemotherapy dose regimen of Myocet in combination with paclitaxel and intravenous Herceptin and will evaluate the efficacy and safety of this dose regimen in patients with metastatic or locally advanced breast cancer and HER2 overexpression. The anticipated time on study treatment is 3-12 months.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received an initial loading dose of trastuzumab 4 milligrams per kilogram (mg/kg), intravenously (IV), over 1.5 hours during Week 1, followed by 2 mg/kg, IV, over 30 minutes once per week from Week 2 to Week 52 or until disease progression. Participants also received myocet, 40 mg/ square meter (m\^2), IV, every 3 weeks, from Week 1; if no dose limiting toxicity (DLT) was observed in greater than or equal to (≥) two-thirds (2/3) of cohort for 2 treatment cycles, the dose was increased to 50 mg/m\^2, IV, and continued for 6 cycles. Participants also received paclitaxel 60 mg/ m\^2, IV, once per week, from Week 19; if no DLT was observed in ≥ 2/3 of cohort for 2 treatment cycles, the dose was increased to 70 mg/m\^2, IV, and subsequently 80 mg/m\^2, IV, and continued until disease progression.
Drug: trastuzumab · Drug: paclitaxel · Drug: Myocet
Participants received an initial loading dose of trastuzumab 4 mg/kg, IV, over 1.5 hours during Week 1, followed by 2 mg/kg, IV, over 30 minutes once per week from Week 2 to Week 52 or until disease progression. Participants also received myocet, 50 mg/m\^2, IV, every 3 weeks, from Week 1 for 6 cycles. Participants also received paclitaxel 80 mg/m\^2, IV, once per week, from Week 19 until disease progression.
Drug: trastuzumab · Drug: paclitaxel · Drug: Myocet
Initial loading does of 4 mg/kg IV, followed by 2 mg/kg IV weekly, until disease progression
Also known as: Herceptin
60 mg/m\^2 IV weekly; dose increased to 70 mg/m\^2, and subsequently 80 mg/m\^2, after 2 treatment cycles with no evidence of DLT until disease progression
40 mg/m\^2 IV weekly; dose increased to 50 mg/m\^2 IV after 2 treatment cycles with no evidence of DLT for 6 cycles
Percentage of Participants Achieving Complete Response (CR) or Partial Response (PR) According to World Health Organization (WHO) Handbook for Reporting Results of Cancer Treatment
For measurable disease, CR was defined as the disappearance of all clinically detectable disease determined by 2 observations not less than 4 weeks apart; and PR was defined as a 50 percent (%) decrease in the sum of the products of the 2 greatest diameters of all measurable lesions by 2 observations not less than 4 weeks apart, and no appearance of new lesions or progression of any lesion. For immeasurable disease, CR was defined as the complete disappearance of all known disease for at least 4 weeks; and PR was defined as an estimated decrease in tumor size of 50% or more for at least 4 weeks.
Time frame: Baseline (BL), Weeks 7, 13, 19, every 8 weeks thereafter until end of study (for up to 3 years)
Time to Disease Progression - Percentage of Participants With an Event
Disease progression was defined as the time from the start of treatment to the date of the first recorded incident of disease progression, or the date of death due any cause. For measurable disease, disease progression was defined as a ≥25% increase in the sum of the products of diameters of 1 or more measurable lesions with a minimal area of greater than (\>)2 square centimeters (cm\^2), or the appearance of new lesions; and for malignant lesions with a minimal area of 2 cm\^2, an increase of ≥1 cm\^2. For immeasurable disease, disease progression was defined as the appearance of any new lesion not previously identified or an estimated increase of ≥50% in existent lesions.
Time frame: BL, Weeks 7, 13, 19, every 8 weeks thereafter until end of study (for up to 3 years)
Time to Disease Progression
The median time, in months, from the start of treatment to disease progression event.
Time frame: BL, Weeks 7, 13, 19, every 8 weeks thereafter until end of study (for up to 3 years)
Time to Treatment Response - Percentage of Participants With an Event
Treatment response was defined as the time from the start of treatment to the date of recorded CR or PR of measurable disease.
Time frame: BL, Weeks 7, 13, 19, every 8 weeks thereafter until end of study (for up to 3 years)
Time to Treatment Response
The median time, in months, from the start of treatment to treatment response event.
Time frame: BL, Weeks 7, 13, 19, every 8 weeks thereafter until end of study (for up to 3 years)
Duration of Response - Percentage of Participants With an Event
Duration of response was defined as the time from date CR was first recorded to the date progressive disease (PD) was first noted. For measurable disease, PD was defined as a ≥25% increase in the sum of the products of diameters of 1 or more measurable lesions with a minimal area of \>2 cm\^2, or the appearance of new lesions; and for malignant lesions with a minimal area of 2 cm\^2, an increase of ≥1 cm\^2. For immeasurable disease, PD was defined as the appearance of any new lesion not previously identified or an estimated increase of ≥50% in existent lesions.
Time frame: BL, Weeks 7, 13, 19, every 8 weeks thereafter until end of study (for up to 3 years)
Duration of Response
The median time, in months, from enrollment to duration of response event to Week 52.
Time frame: BL, Weeks 7, 13, 19, every 8 weeks thereafter until end of study (for up to 3 years)
Time to Therapy Failure - Percentage of Participants With an Event
Therapy failure was defined as the date of the start of therapy to the date of withdrawal due to adverse events, progressive disease/insufficient therapeutic response, death, failure to return, or refusal of treatment/lack of cooperation/withdrawal of consent. Participants were censored at the last dose of treatment if no event was recorded.
Time frame: BL, Weeks 7, 13, 19, every 8 weeks thereafter until end of study (for up to 3 years)
Time to Therapy Failure
The median time, in months, from treatment start to therapy failure event. Participants were censored at the last date of treatment if no event was recorded.
Time frame: BL, Weeks 7, 13, 19, every 8 weeks thereafter until end of study (for up to 3 years)
Overall Survival (OS) - Percentage of Participants With an Event
OS was defined as the time from the date of the start of treatment to the date of death or the last date the participant was known to be alive.
Time frame: BL, Weeks 7, 13, 19, every 8 weeks thereafter until end of study (for up to 3 years)
Overall Survival
The time, in months, from the start of treatment to OS event. The mean survival time and it's standard error were underestimated because the largest observation was censored and the estimation was restricted to the largest event time.
Time frame: BL, Weeks 7, 13, 19, every 8 weeks thereafter until end of study (for up to 3 years)
| Milestone | Trastuzumab, Doxorubicin, Paclitaxel; Phase I | Trastuzumab, Doxorubicin, Paclitaxel; Phase II | Trastuzumab Doxorubicin, Paclitaxel; Phase I and Phase II |
|---|---|---|---|
| Started | 15 | 48 | 6 |
| Completed | 6 | 14 | 3 |
| Not completed | 9 | 34 | 3 |
| Withdrew: Adverse event | 2 | 18 | 0 |
| Withdrew: Lack of efficacy | 2 | 4 | 0 |
| Withdrew: Protocol violation | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 1 | 7 | 1 |
| Withdrew: Administrative reasons | 0 | 3 | 1 |
| Withdrew: Death | 0 | 1 | 0 |
| Withdrew: Disease progression | 3 | 1 | 1 |
For measurable disease, CR was defined as the disappearance of all clinically detectable disease determined by 2 observations not less than 4 weeks apart; and PR was defined as a 50 percent (%) decrease in the sum of the products of the 2 greatest diameters of all measurable lesions by 2 observations not less than 4 weeks apart, and no appearance of new lesions or progression of any lesion. For immeasurable disease, CR was defined as the complete disappearance of all known disease for at least 4 weeks; and PR was defined as an estimated decrease in tumor size of 50% or more for at least 4 weeks.
| percentage of participants | Trastuzumab, Doxorubicin, Paclitaxel; Phase II |
|---|---|
| CR | 51.85 |
| PR | 46.30 |
Disease progression was defined as the time from the start of treatment to the date of the first recorded incident of disease progression, or the date of death due any cause. For measurable disease, disease progression was defined as a ≥25% increase in the sum of the products of diameters of 1 or more measurable lesions with a minimal area of greater than (\>)2 square centimeters (cm\^2), or the appearance of new lesions; and for malignant lesions with a minimal area of 2 cm\^2, an increase of ≥1 cm\^2. For immeasurable disease, disease progression was defined as the appearance of any new lesion not previously identified or an estimated increase of ≥50% in existent lesions.
| percentage of participants | Trastuzumab, Doxorubicin, Paclitaxel; Phase II |
|---|---|
| Time to Disease Progression - Percentage of Participants With an Event | 40.74 |
The median time, in months, from the start of treatment to disease progression event.
| months | Trastuzumab, Doxorubicin, Paclitaxel; Phase II |
|---|---|
| Time to Disease Progression | 43.3018 (24.0821 to NA) |
Treatment response was defined as the time from the start of treatment to the date of recorded CR or PR of measurable disease.
| percentage participants | Trastuzumab, Doxorubicin, Paclitaxel; Phase II |
|---|---|
| Time to Treatment Response - Percentage of Participants With an Event | 98.15 |
The median time, in months, from the start of treatment to treatment response event.
| months | Trastuzumab, Doxorubicin, Paclitaxel; Phase II |
|---|---|
| Time to Treatment Response | 1.87269 (1.83984 to 1.93840) |
Duration of response was defined as the time from date CR was first recorded to the date progressive disease (PD) was first noted. For measurable disease, PD was defined as a ≥25% increase in the sum of the products of diameters of 1 or more measurable lesions with a minimal area of \>2 cm\^2, or the appearance of new lesions; and for malignant lesions with a minimal area of 2 cm\^2, an increase of ≥1 cm\^2. For immeasurable disease, PD was defined as the appearance of any new lesion not previously identified or an estimated increase of ≥50% in existent lesions.
| percentage of participants | Trastuzumab, Doxorubicin, Paclitaxel; Phase II |
|---|---|
| Duration of Response - Percentage of Participants With an Event | 39.62 |
The median time, in months, from enrollment to duration of response event to Week 52.
| months | Trastuzumab, Doxorubicin, Paclitaxel; Phase II |
|---|---|
| Duration of Response | 41.1006 (20.9610 to NA) |
Therapy failure was defined as the date of the start of therapy to the date of withdrawal due to adverse events, progressive disease/insufficient therapeutic response, death, failure to return, or refusal of treatment/lack of cooperation/withdrawal of consent. Participants were censored at the last dose of treatment if no event was recorded.
| percentage of participants | Trastuzumab, Doxorubicin, Paclitaxel; Phase II |
|---|---|
| Time to Therapy Failure - Percentage of Participants With an Event | 81.48 |
The median time, in months, from treatment start to therapy failure event. Participants were censored at the last date of treatment if no event was recorded.
| months | Trastuzumab, Doxorubicin, Paclitaxel; Phase II |
|---|---|
| Time to Therapy Failure | 24.0821 (17.5113 to 35.6797) |
OS was defined as the time from the date of the start of treatment to the date of death or the last date the participant was known to be alive.
| percentage of participants | Trastuzumab, Doxorubicin, Paclitaxel; Phase II |
|---|---|
| Overall Survival (OS) - Percentage of Participants With an Event | 3.70 |
The time, in months, from the start of treatment to OS event. The mean survival time and it's standard error were underestimated because the largest observation was censored and the estimation was restricted to the largest event time.
| months | Trastuzumab, Doxorubicin, Paclitaxel; Phase II |
|---|---|
| Overall Survival | 7.6909 ± 0.1338 |
Collected over BL, and Weeks 7, 13, 19, every 8 weeks thereafter until end of study.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Trastuzumab, Doxorubicin, Paclitaxel; Phase I & II | — | 26/69 (37.7%) | 63/69 (91.3%) |
| Event | Trastuzumab, Doxorubicin, Paclitaxel; Phase I & II |
|---|---|
| Febrile neutropeniaGeneral disorders | 12/69 |
| Cardiac failure NOSCardiac disorders | 2/69 |
| CoughRespiratory, thoracic and mediastinal disorders | 2/69 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 2/69 |
| Diarrhoea NOSGastrointestinal disorders | 2/69 |
| Pneumonia NOSRespiratory, thoracic and mediastinal disorders | 2/69 |
| Interstitial lung diseaseRespiratory, thoracic and mediastinal disorders | 1/69 |
| Metastases to central nervous systemNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/69 |
| Intestinal obstruction NOSGastrointestinal disorders | 1/69 |
| EndocarditisInfections and infestations | 1/69 |
| Event | Trastuzumab, Doxorubicin, Paclitaxel; Phase I & II |
|---|---|
| AlopeciaSkin and subcutaneous tissue disorders | 54/69 |
| Mucosal inflammation NOSRespiratory, thoracic and mediastinal disorders | 40/69 |
| NauseaGastrointestinal disorders | 36/69 |
| AstheniaGeneral disorders | 35/69 |
| Diarrhoea NOSGastrointestinal disorders | 29/69 |
| Vomiting NOSGastrointestinal disorders | 26/69 |
| Nail disorder NOSGeneral disorders | 23/69 |
| PyrexiaGeneral disorders | 23/69 |
| NeutropeniaBlood and lymphatic system disorders | 21/69 |
| Oedema peripheralGeneral disorders | 19/69 |
| Age, Continuous(years) | Trastuzumab, Doxorubicin, Paclitaxel; Phase I | Trastuzumab, Doxorubicin, Paclitaxel; Phase II | Trastuzumab, Doxorubicin, Paclitaxel; Phase II and II | Total |
|---|---|---|---|---|
| Mean | 54.73 ± 12.42 | 52.98 ± 12.33 | 44.33 ± 15.36 | 52.61 ± 12.70 |
| Sex: Female, Male(Participants) | Trastuzumab, Doxorubicin, Paclitaxel; Phase I | Trastuzumab, Doxorubicin, Paclitaxel; Phase II | Trastuzumab, Doxorubicin, Paclitaxel; Phase II and II | Total |
|---|---|---|---|---|
| Female | 15 | 48 | 6 | 69 |
| Male | 0 | 0 | 0 | 0 |
The record gives a start of Jul 2001, a primary completion of Sep 2009 and a completion of Sep 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2015, 5 years 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Trastuzumab · Paclitaxel · Doxorubicin